Pertuzumab?

Pertuzumab (brand name Perjeta®)
A humanized IgG1 monoclonal antibody that targets the extracellular domain of the HER2/neu receptor. It’s mainly used in combination with trastuzumab (Herceptin®) and a taxane (docetaxel or paclitaxel) for HER2‑positive breast cancer.

---

1. Indications

Setting	Approved Use (US/EMA)
Metastatic HER2‑positive breast cancer	First‑line combination: Pertuzumab + trastuzumab + docetaxel
Early‑stage (adjuvant) HER2‑positive breast cancer	Pertuzumab + trastuzumab + chemotherapy (anthracycline‑based or non‑anthracycline)
Neoadjuvant (pre‑operative) HER2‑positive breast cancer	Pertuzumab + trastuzumab + chemotherapy

Off‑label: In clinical trials, pertuzumab has been explored in HER2‑positive gastric/GEJ cancers, HER2‑positive metastatic colorectal cancer, and other solid tumors, but these uses are not FDA/EMA approved.

---

2. Mechanism of Action

• HER2 blockade: Binds to subdomain II of the HER2 extracellular domain, preventing HER2 dimerization with other HER receptors (HER3, HER1, etc.).
• Synergy with trastuzumab: Trastuzumab binds subdomain IV and mediates antibody‑dependent cellular cytotoxicity (ADCC). The two antibodies together more effectively inhibit HER2 signaling.
• Cell‑cycle arrest & apoptosis: Down‑regulation of downstream pathways (PI3K/AKT, MAPK) reduces proliferation and induces cell death.

---

3. Pharmacokinetics

Parameter	Typical Value
Half‑life	~12–18 days (steady‑state ~6–8 weeks)
Clearance	Non‑linear; primarily through catabolism in the reticulo‑endothelial system
Volume of distribution	~12–15 L (consistent with monoclonal antibodies)
Administration	Intravenous infusion (slow, 60–120 min)
Dosing schedule	840 mg IV loading dose, then 420 mg IV every 3 weeks (q3w) with trastuzumab; 840 mg IV every 3 weeks (q3w) with docetaxel (in the metastatic setting).

Note: Because pertuzumab is a large protein, oral bioavailability is essentially zero; it must be given IV.

---

4. Dosing & Administration

4.1. Metastatic Breast Cancer (Combination with Trastuzumab & Docetaxel)

• Loading dose: 840 mg IV (over 60–120 min) on Day 1 of Cycle 1.
• Maintenance: 420 mg IV every 3 weeks (Day 1 of each cycle).
• Concurrent trastuzumab: 4 mg/kg IV loading dose (or 600 mg), then 2 mg/kg IV q3w.
• Docetaxel: 75 mg/m² IV q3w (often with corticosteroid premedication to reduce hypersensitivity).

4.2. Early‑Stage (Adjuvant/Neoadjuvant) Breast Cancer

• Loading dose: 840 mg IV on Day 1 of Cycle 1.
• Maintenance: 420 mg IV q3w for 16 weeks (total of 6 infusions).
• Trastuzumab & chemotherapy per institutional protocol (often 4 mg/kg IV every 3 weeks + anthracycline or taxane).

Tip: The first infusion is usually performed in a monitored setting (e.g., infusion center) because of the risk of infusion reactions.

---

5. Common Adverse Events

Category	Typical Incidence
Infusion reactions	10–20 % (rash, pruritus, fever, chills, hypotension) – often mild, treatable with slowing the infusion or antihistamines.
Gastrointestinal	Diarrhea (10–20 %), nausea, vomiting (rare).
Hematologic	Anemia, neutropenia (especially when combined with docetaxel).
Cardiac	LVEF decline (rare, <5 % in trials), but monitor by echocardiogram or MUGA before each cycle.
Pulmonary	Interstitial lung disease/fibrosis (rare, <1 %).
Other	Fatigue, headache, arthralgia, mucositis.

Key point: Cardiac toxicity is mainly a concern when pertuzumab is combined with trastuzumab and anthracyclines. LVEF should be checked at baseline, every 3 months for the first year, then annually if stable.

---

6. Contraindications & Precautions

• Contraindications

  • Known hypersensitivity to pertuzumab or any component of the formulation.
  • Active uncontrolled infection.

• Precautions

  • Cardiac disease: History of heart failure, cardiomyopathy, or significant arrhythmias – require close monitoring.
  • Pregnancy & lactation: Category B (animal studies have not shown risk; no adequate human studies). Generally avoid unless benefits outweigh risks; not recommended for lactation.
  • Immunosuppression: Be cautious in patients with compromised immune systems; risk of serious infections.
  • Concurrent therapies: Avoid simultaneous use of other monoclonal antibodies targeting HER2 (unless part of a clinical protocol).

---

7. Drug Interactions

• Limited interactions because pertuzumab is a biologic.
• Co‑administered chemotherapies:
  • Docetaxel & trastuzumab: increase hematologic toxicity (neutropenia).
  • Anthracyclines: potential for additive cardiotoxicity.
• Corticosteroids: used as premedication for docetaxel may increase infection risk; monitor for hyperglycemia.
• Anticoagulants: No direct interaction, but monitor for bleeding if the patient has thrombocytopenia.

---

8. Monitoring

Parameter	Frequency
Baseline labs	CBC, CMP, LFTs, LVEF (echo/MUGA)
During treatment	CBC & CMP before each cycle, LVEF every 3–4 cycles (if on trastuzumab/anthracycline).
Infusion	Vital signs before, during, and after each infusion.
Adverse events	Immediate reporting of grade ≥ 3 symptoms (e.g., severe fatigue, cardiac symptoms).

---

9. Practical Tips for Patients & Caregivers

Scenario	Action
Feeling shortness of breath or chest pain	Stop infusion, contact provider immediately (possible cardiac event).
Diarrhea lasting >48 h	Hydration, antidiarrheal (loperamide), notify provider for possible dose adjustment.
Fever or infection signs	Promptly seek medical attention; consider dose hold if severe.
Pregnancy concerns	Discuss contraception and pregnancy testing before starting.
Travel or infusion scheduling	Coordinate with infusion center; bring medical alert card indicating pertuzumab therapy.

---

10. Key Take‑aways

• Pertuzumab is a powerful HER2‑targeting antibody that works best in combination with trast